Investigation of the Effects of Medium Cut-off Dialyzers Versus High-Flux Dialyzers on Clinical and Laboratory Parameters of Prevalent Hemodialysis Patients

Depressive Disorder Clinical Trial

Official title:

Investigation of the Effects of Medium Cut-off Dialyzers Versus High-Flux Dialyzers on Clinical and Laboratory Parameters of Prevalent Hemodialysis Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05698420
• Other study ID #: MCOx_MAIEAH_001
• Status: Completed
• Start date: March 1, 2020
• Est. completion date: October 31, 2020

Study information

• Verified date: May 2024
• Source: Sanliurfa Mehmet Akif Inan Education and Research Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In this study, the investigators aimed to observe the effects of medium cut-off dialysis filters and high-flux dialysis filters on malnutrition inflammation score, uremic itching, restless leg syndrome, anemia, and ESA treatment, which are prominent complications in hemodialysis, and routine follow-up parameters.

Description:

The study is designed as a single-center, prospective, observational research. A total of 50 stable-course chronic hemodialysis patients over 18 years of age and treated for at least 3 months will be included in the study and the study period will be planned for 12 months. 25 of the 50 chronic hemodialysis patients planned to be included in the study will use MCO-membrane and the other 25 will use high-flux membrane. The distribution of patients to the high-flux membrane and MCO membrane groups will be done randomly (sequentially single-pair number method). Then, the standard 12-hour (3x4 hours/week) hemodialysis treatment will continue. At the beginning of the study (0.), at the end of the third (3.) month and at the end of the sixth (6.) month;

Monthly laboratory tests routinely performed on hemodialysis patients (tests routinely performed in hemodialysis patient follow-up) 5 ml blood samples will be taken from the hemodialysis set to determine the levels of medium-large molecule-weight toxins-wastes and inflammatory parameters before and after dialysis, and the sera will be separated and stored at -80oC for use at the end of the study.

Automatic blood pressure measurement will be performed before and after hemodialysis to evaluate arterial stiffness.

The Malnutrition Inflammation Score will be applied to evaluate the nutritional status (the MIS form is given in the appendix) Visual Analog Scale will be used for appetite Visual Analog Scale will be used for uremic pruritus Depression scale screening (Beck's scale)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: October 31, 2020
• Est. primary completion date: September 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Chronic hemodialysis patients

• Patients continuing the hemodialysis program for at least 3 months

• Patients over 18 years of age

Exclusion Criteria:

• Patients with advanced heart failure, malignancy, terminal illness

• Patients with active infectious disease

• Acute hemodialysis patients

• Patients vascular access dysfunction

Related Conditions & MeSH terms

• Anemia of Chronic Kidney Disease
• Cachexia
• Depressive Disorder
• Inflammation
• Kidney Diseases
• Malnutrition
• Pruritus
• Renal Insufficiency, Chronic
• Restless Legs Syndrome
• Syndrome

Intervention

Device:
• Dialysis using the Theranova-400 device.
Patients receive hemodialysis treatment using the Theranova-400 dialyzer.
• Dialysis using the FX80 device.
Patients receive hemodialysis treatment using the FX80 dialyzer.

Locations

Country	Name	City	State
Turkey	Mehmet Akif Inan Training and Research Hospital	Sanliurfa	Karaköprü

Sponsors (1)

Lead Sponsor	Collaborator
Sanliurfa Mehmet Akif Inan Education and Research Hospital

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Malnutrition-inflammation score (MIS)	At the start of the study, the malnutrition-inflammation score will be recorded. This score ranges from 0 to 30, with higher scores indicating worse outcomes.	Prior to randomization, at the start of the study.
Primary	Malnutrition-inflammation score (MIS)	The malnutrition-inflammation score will be recorded at the conclusion of the study. This score ranges from 0 to 30, with higher scores indicating worse outcomes.	At the end of the 6th month after randomization.
Primary	Depressive disorder	At the start of the study, the Beck's depression scale will be recorded. This score ranges from 0 to 63, with higher scores indicating worse depression.	Prior to randomization, at the start of the study.
Primary	Depressive disorder	At the conclusion of the study, the Beck's depression scale will be recorded. This score ranges from 0 to 63, with higher scores indicating worse depression.	At the end of the 6th month after randomization.
Primary	Uremic pruritus	At the start of the study, the visual analog scale for pruritus will be recorded. This score ranges from 0 to 10, with higher scores indicating worse itching.	Prior to randomization, at the start of the study.
Primary	Uremic pruritus	At the conclusion of the study, the visual analog scale for pruritus will be recorded. This score ranges from 0 to 10, with higher scores indicating worse itching.	At the end of the 6th month after randomization.
Primary	Restless leg syndrome	At the start of the study, the Restless Leg Syndrome screening questionnaire will be administered. This score ranges from 0 to 40, with higher scores indicating worse symptoms.	Prior to randomization, at the start of the study.
Primary	Restless leg syndrome	At the conclusion of the study, the Restless Leg Syndrome screening questionnaire will be administered. This score ranges from 0 to 40, with higher scores indicating worse symptoms.	At the end of the 6th month after randomization.
Primary	Appetite	At the start of the study, the visual analog scale of appetite will be recorded. This score ranges from 0 to 5, with higher scores indicating better appetite.	Prior to randomization, at the start of the study.
Primary	Appetite	At the conclusion of the study, the visual analog scale of appetite will be recorded. This score ranges from 0 to 5, with higher scores indicating better appetite.	At the end of the 6th month after randomization.
Primary	Hemoglobin	Hemoglobin levels will be measured on a monthly basis.	March 2020
Primary	Hemoglobin	Hemoglobin levels will be measured on a monthly basis.	April 2020
Primary	Hemoglobin	Hemoglobin levels will be measured on a monthly basis.	May 2020
Primary	Hemoglobin	Hemoglobin levels will be measured on a monthly basis.	June 2020
Primary	Hemoglobin	Hemoglobin levels will be measured on a monthly basis.	July 2020
Primary	Hemoglobin	Hemoglobin levels will be measured on a monthly basis.	August 2020
Primary	Hemoglobin	Hemoglobin levels will be measured on a monthly basis.	September 2020
Primary	Erythropoietin Doses	Weight-adjusted doses of erythropoietin will be prescribed on a monthly basis.	March 2020
Primary	Erythropoietin Doses	Weight-adjusted doses of erythropoietin will be prescribed on a monthly basis.	April 2020
Primary	Erythropoietin Doses	Weight-adjusted doses of erythropoietin will be prescribed on a monthly basis.	May 2020
Primary	Erythropoietin Doses	Weight-adjusted doses of erythropoietin will be prescribed on a monthly basis.	June 2020
Primary	Erythropoietin Doses	Weight-adjusted doses of erythropoietin will be prescribed on a monthly basis.	July 2020
Primary	Erythropoietin Doses	Weight-adjusted doses of erythropoietin will be prescribed on a monthly basis.	August 2020
Primary	Erythropoietin Doses	Weight-adjusted doses of erythropoietin will be prescribed on a monthly basis.	September 2020
Primary	Phosphorus levels control	Serum phosphorus levels will be tested on a monthly basis.	March 2020
Primary	Phosphorus levels control	Serum phosphorus levels will be tested on a monthly basis.	April 2020
Primary	Phosphorus levels control	Serum phosphorus levels will be tested on a monthly basis.	May 2020
Primary	Phosphorus levels control	Serum phosphorus levels will be tested on a monthly basis.	June 2020
Primary	Phosphorus levels control	Serum phosphorus levels will be tested on a monthly basis.	July 2020
Primary	Phosphorus levels control	Serum phosphorus levels will be tested on a monthly basis.	August 2020
Primary	Phosphorus levels control	Serum phosphorus levels will be tested on a monthly basis.	September 2020
Primary	Parathyroid hormone levels control	Serum parathyroid hormone levels will be tested on a monthly basis.	March 2020
Primary	Parathyroid hormone levels control	Serum parathyroid hormone levels will be tested on a monthly basis.	April 2020
Primary	Parathyroid hormone levels control	Serum parathyroid hormone levels will be tested on a monthly basis.	May 2020
Primary	Parathyroid hormone levels control	Serum parathyroid hormone levels will be tested on a monthly basis.	June 2020
Primary	Parathyroid hormone levels control	Serum parathyroid hormone levels will be tested on a monthly basis.	July 2020
Primary	Parathyroid hormone levels control	Serum parathyroid hormone levels will be tested on a monthly basis.	August 2020
Primary	Parathyroid hormone levels control	Serum parathyroid hormone levels will be tested on a monthly basis.	September 2020